Therapeutic Drug Monitoring (TDM) of Cyclosporine in Kidney Transplant Patients by Dried Blood Spot Assay. Interest and Feasibility.

NCT02830191 | Completed

• 1 other identifier: 14-050
• Study Type: observational
• Target: 22
• Locations: 0 countries
• Sites: N/A

Brief Summary

Ciclosporin A (CsA) is an immunosuppressive drug used in organs and tissues transplantations (kidney, heart, liver, bone marrow ...) to prevent rejection, and in different autoimmune or inflammatory diseases. A therapeutic drug monitoring (TDM) is required during a CsA treatment. It is justified by a narrow therapeutic range between efficiency and nephrotoxicity, and by large intra- and interindividual pharmacokinetic variability. TDM of CsA is conventionally performed by determining residual concentration, and sometimes concentration at 2 hours after administration. TDM of CsA is currently performed by venous sampling on ethylenediaminetetraacetic acid (EDTA). Dried blood spot (DBS) sampling could be a particularly interesting alternative to conventional blood sampling. With DBS, capillary blood is obtained from a finger prick by the patient himself, and the blood drop obtained is deposited on filter paper, which can be stored at room temperature and then be sent to the laboratory by mail. This sampling method has several advantages : it requires small blood volumes, it is less invasive than conventional venous sampling, sampling can be performed by the patient himself at home few days before the consultation, and the results of the analysis can be available to the clinician on the day of consultation, allowing dose adjustment more quickly. Several studies have been published in recent years using DBS sampling method, for various drugs such as antimalarials, antiepileptics, antiretrovirals, metformin, benzodiazepines, or immunosuppressants. Only one clinical validation study of TDM of CsA using DBS method was published by Wilhelm et al. (2013) in a population of 38 patients who received allogeneic stem cell transplant recipients. The results showed excellent correlation between the concentrations determined by the two sampling methods. The investigators propose an observational study at the University Hospital of Caen for clinical validation of DBS sampling for TDM of CsA in kidney transplantation, for which there are no data published. During a nephrology consultation, for each patient, venous and finger prick blood samples are simultaneously collected. CsA assays were performed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) for the two sampling methods. A specific LC-MS/MS assay method applied for DBS samples was developed and validated for this study (DBS/LC-MS/MS). Correlation between the results obtained from the two sampling methods will be evaluated, on at least 100 samples. Patients have to answer a questionnaire to assess pain and comfort of DBS sampling, and feasibility of self-sampling at home by this method. The aim of this clinical validation study of DBS sampling is the establishment of the systematic TDM of CsA for renal transplant patients by DBS sampling at the University Hospital of Caen.

Conditions

Kidney Transplantation

Keywords

Cyclosporine, Dried blood spot

Outcome Measures

Primary Outcomes (1)

• Correlation between CsA concentrations determined from DBS sampling and conventional venous sampling for each patient (coefficient correlation, Bland-Altman difference plot)

  8 months

Secondary Outcomes (1)

• Comparison of pain, comfort and practicality of the two sampling methods by a patient questionnaire.

  8 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Renal transplant patients treated with cyclosporine at nephrology department of the University Hospital of Caen.

You may qualify if:

• Adult Patient (18 years or older) treated with CsA and monitored for dose adjustment
• Kidney transplantation
• Not objecting to participate in study

You may not qualify if:

• Objecting to the additional sample by finger prick
• Anticoagulant treatment
• Hemostatic disorder (risk of hematoma)

Sponsors & Collaborators

• University Hospital, Caen: lead

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 6, 2016
• First Posted: July 12, 2016
• Study Start: November 1, 2014
• Primary Completion: July 1, 2015
• Study Completion: July 1, 2015
• Last Updated: April 18, 2019

Record last verified: 2016-07

Data Sharing

• IPD Sharing: Will share